The COVID-19 pandemic has highlighted the importance of public health and hygiene and led to a significant increase in the demand for antiviral products.<\/p>\n
As the world continues to grapple with the ongoing pandemic and its variants, people have become more aware of the importance of protecting themselves from viral infections. This increased awareness has led to a surge in demand for products that can help prevent the spread of the virus.<\/p>\n
Antiviral products are designed to prevent the replication of viruses or to neutralize their effects. These products include hand sanitizers, surface disinfectants, face masks, and air purifiers, among others.<\/p>\n
As the pandemic continues to evolve, the demand for antiviral products is expected to remain high. Consumers are likely to continue to prioritize hygiene and cleanliness and may continue to direct spending toward these products for years to come.<\/p>\n
In addition, the experience of the pandemic has raised awareness of the potential risks associated with viral infections, and people may be more inclined to take precautions to avoid such risks in the future. It\u2019s a form of PTSD on a collective level that has major implications for industry and investment.<\/p>\n
Companies that manufacture or distribute antiviral solutions are poised to see a surge in demand and may need to adjust production rates and supply chains to meet this demand. This may create new opportunities for innovation and investment in the field of antiviral technologies.<\/p>\n
The likelihood of increased demand for antiviral products in the wake of the pandemic is high, and this trend is likely to continue for the foreseeable future. With that in mind, we take a look below at sustainable growth opportunities poised to profit from the secular impact of the pandemic over coming years.<\/p>\n
<\/p>\n
Clorox Co. (NYSE:CLX)<\/strong> engages in the manufacture and marketing of consumer and professional products. It operates through its Health and Wellness, Household, Lifestyle, and International segments.<\/p>\n The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segments consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment refers to food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment covers products sold outside the United States, excluding natural personal care products.<\/p>\n Clorox Co. (NYSE:CLX) recently announced that it has earned the top ranking on Barron’s 2023 100 Most Sustainable Companies list \u2014 its second time in the top five and fifth consecutive year in the top 25 since the rankings were first released in 2018. Clorox was selected for its continued efforts around sustainability, diversity, and transparency.<\/p>\n “Sustainability is built into the fiber of our purpose to champion people to be well and thrive every single day,” said CEO Linda Rendle. “This recognition reflects our unwavering commitment to fully integrate environmental, social and governance performance into our daily business. While we’re incredibly proud of this achievement, we still have more work ahead to continue making positive change for our teammates, communities, shareholders and planet.”<\/p>\n And the stock has been acting well over recent days, up something like 3% in that time. CLX shares have been relatively flat over the past month of action, with very little net movement during that period.<\/p>\n Clorox Co. (NYSE:CLX) managed to rope in revenues totaling $1.7B in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 1.4%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($168M against $1.9B, respectively).<\/p>\n <\/p>\n Plandai Biotechnology Inc. (OTC US:PLPL)<\/strong> is a very interesting ultra-cheap newcomer in this space with the potential to become a star from very deep discount levels, and speculators should take note.<\/p>\n The company announced this morning that it has entered into a binding memorandum of understanding to close a share exchange agreement with Good Salt, LLC, a Florida limited liability company. Good Salt is the successor in interest to material tangible and intangible assets, cash and cash equivalents, inventory, and the active operations of two Florida limited liability companies, ByoPlanet International, LLC, and Clean Republic, LLC. The upshot is quite simply that PLPL is now headed toward being a legitimate player in this high-growth space.<\/p>\n Plandai Biotechnology Inc. (OTC US:PLPL) is now moving, through its binding MOU, toward being a health and technology company that markets and sells an electrostatic chemical cleansing delivery system. ByoPlanet, using its patented “Induction Charged Technology™,” certified by the Global Biorisk Advisory Council (GBAC), and proprietary chemistry through its Clean Republic label, delivers \u201ceffective and safe infection prevention solutions, providing a proprietary complete and uniform disinfectant coverage of any surface, in less time with less solution, and without the threat of cross-contamination.\u201d<\/p>\n According to PLPL\u2019s release, ByoPlanet’s focus is to market and sell its products in a variety of settings, including animal health, plant health, commercial cleaning, restoration, pest control, and public services. Plandai will acquire all of the outstanding interests in Good Salt in exchange for Plandai restricted common stock and Series “A” Preferred stock, resulting in Plandai acquiring the ByoPlanet and Clean Republic assets and business. Since 2020, ByoPlanet has manufactured over 85,000 units for customers around the world, including Fortune 100 companies in industries like Property Restoration, Hospitality, and Animal Health.<\/p>\n “I couldn’t be more excited about what this collaboration means for our customers,” said Rick O’Shea, CEO of ByoPlanet. “Our commitment to providing the latest and most innovative health and wellness products has always been a top priority, and this exciting development only reinforces that dedication. I can’t wait to see the potential opportunities that may come from this collaboration, and I’m eager to continue building upon our reputation as industry leaders. Our customers deserve the very best, and we’re committed to delivering just that.”<\/p>\n ByoPlanet’s system significantly reduces viruses and pathogens using electrostatic technology that reaches around any surface regardless of shape, allowing for more effective disinfection and up to 75% faster applications using less than half as much disinfection solution. This type of electrostatic spraying improves indoor air quality and eliminates virus and other particulates in the air, including mold. The result is more effective disinfection and significant cost savings for a variety of businesses and institutions.<\/p>\n Plandai Biotechnology Inc. (OTC US:PLPL) CEO, Tad Mailander, noted, “The closing of this binding share exchange marks a significant shift in Plandai’s direction, as we align ourselves with a dedicated team producing an important technology for the world. We are excited about the potential opportunities this new direction presents and are committed to leveraging our combined expertise and resources to drive innovation and growth. This is a testament to our unwavering commitment to making a positive impact in the world, and we look forward to continuing to push the boundaries of what’s possible.”<\/p>\n <\/p>\n Henry Schein Inc. (Nasdaq:HSIC)<\/strong> engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments.<\/p>\n The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins. The Technology and Value-Added Services segment offers financial on a non-recourse basis, network, and hardware services.<\/p>\n Henry Schein Inc. (Nasdaq:HSIC) recently announced has been recognized by Ethisphere, a global leader in defining and advancing the standards of ethical business practices, as one of the 2023 World\u2019s Most Ethical Companies. Henry Schein has been recognized 12 times and is the only honoree in the Healthcare Products industry. In 2023, 135 honorees spanning 19 countries and 46 industries were recognized.<\/p>\n “On behalf of the more than 22,000 Team Schein Members, we are pleased to once again be recognized by Ethisphere as one of the World’s Most Ethical Companies,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “Our commitment to the success of the stakeholders that make up our \u2018Mosaic of Success\u2019 \u2013 Team Schein Members, Customers, Supplier Partners, Shareholders, and Society \u2013 has long been the foundation of our purpose-driven approach to business. Fulfilling this commitment requires tackling significant external challenges to our collective success, including climate change, health inequities, supply chain resilience, and the underrepresentation of women, ethnic minorities, and other diverse populations in health care, among others. While progress has been made, much work remains, and we are committed to continuing the journey as a socially responsible corporate citizen.”<\/p>\n It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark things. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -7%.<\/p>\n Henry Schein Inc. (Nasdaq:HSIC) has a significant war chest ($117M) of cash on the books, which is balanced by about $2.2B in total current liabilities. HSIC is pulling in trailing 12-month revenues of $12.6B. In addition, the company is seeing major top-line growth, with y\/y quarterly revenues growing at 1.2%.<\/p>\n <\/p>\n Other key names in the antiviral products space<\/strong> include Merck & Co. Inc. (NYSE:MRK), Ecolab Inc. (NYSE:ECL), Kimberly-Clark Corp. (NYSE:KMB), Diversey Holdings Ltd. (Nasdaq:DSEY), Albemarle Corp. (NYSE:ALB), and Church & Dwight Co. (NYSE:CHD).<\/p>\n","protected":false},"excerpt":{"rendered":" The COVID-19 pandemic has highlighted the importance of public health and hygiene and led to a significant increase in the demand for antiviral products. As […]<\/p>\n","protected":false},"author":35,"featured_media":56551,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236,1],"tags":[],"stock_ticker":[14413,16648,14385,14474,16649,16647,14659,13648,13690,13664,16646],"class_list":["post-59622","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-featured","stock_ticker-alb","stock_ticker-chd","stock_ticker-clx","stock_ticker-ecl","stock_ticker-hsic","stock_ticker-kmb","stock_ticker-mrk","stock_ticker-nasdaq","stock_ticker-nyse","stock_ticker-otcmkts","stock_ticker-plpl","entry"],"acf":[],"yoast_head":"\n